| Title |
|
|
|
Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma
|
|
| Author |
|
|
|
|
|
| Abstract |
|
|
|
| Introduction: The majority of patients with locally advanced head and neck squamous cell carcinoma (HNSCC) will recur. The treatment of patients with recurrent/metastatic (R/M HNSCC) is rapidly evolving.Areas covered: This article will comprehensively review the current systemic treatment of R/M HNSCC.Expert commentary: For the time being, the EXTREME regimen (cetuximab in combination with platinum and 5-fluorouracil) still remains standard of care in previously untreated R/M HNSCC patients who are candidates for combination chemotherapy. Single agents with well documented activity in HNSCC include methotrexate, cisplatin, 5-FU, docetaxel, and paclitaxel. The anti-PD-1 monoclonal antibody nivolumab can be considered the current standard of care in patients with R/M HNSCC progressing after platinum-based therapy based on the results of CheckMate 141 showing a survival benefit over standard of care drugs, such as single agent weekly cetuximab, methotrexate, or docetaxel.Multiple randomized phase III trials comparing anti-PD(L)-antibodies either as single agent or in combination with chemotherapy or an anti-CTLA-4 with the EXTREME as fist line treatment are ongoing or planned. The outcome of these trials might change the current treatment paradigm in previously untreated R/M HNSCC. Immunotherapeutic agents under active investigation include Toll-like receptor 8 agonists and inhibitors of IDO1. |
|
|
| Language |
|
|
|
English
|
|
| Source (journal) |
|
|
|
Expert review of anticancer therapy |
|
| Publication |
|
|
|
Abingdon : Taylor & francis ltd, 2018
|
|
| ISSN |
|
|
|
1473-7140
|
|
| Volume/pages |
|
|
|
18:9(2018), p. 901-915
|
|
| ISI |
|
|
|
000441639700007
|
|
| Pubmed ID |
|
|
|
29999437
|
|
| Full text (Publisher's DOI) |
|
|
| |
|
| Full text (publisher's version - intranet only) |
|
|
| |
|